Evidence map›Paper›PMID 36054476›Full record

ArticleTransfusion2022

Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.

Maja Weisser, Nina Khanna, Anemone Hedstueck, Sarah Tschudin Sutter, Sandra Roesch, Gregor Stehle, Mihaela Sava, Nikolaus Deigendesch, Manuel Battegay, Laura Infanti and 22 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. The Impact of Pathogen Reduction on Total IgG and IgG Subclass Profiles of Convalescent Plasma.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 10 institutions in 2 countries.

Maja WeisserDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.ORCID 0000-0002-0134-1929
Nina KhannaDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Anemone HedstueckDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Sarah Tschudin SutterDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Sandra RoeschDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Gregor StehleRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Mihaela SavaDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Nikolaus DeigendeschInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Manuel BattegayDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Laura InfantiRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Andreas HolbroRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Stefano BassettiDepartment of Clinical Research, University Hospital Basel, Basel, Switzerland.
Hans ParggerDepartment of Clinical Research, University Hospital Basel, Basel, Switzerland.
Hans H HirschDivision of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Karoline LeuzingerTransplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Laurent KaiserGeneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
Diem-Lan VuDivision of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
Katharina BaurRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Nadine MassaroRegional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland.
Michael Paul BuschDepartment of Laboratory Medicine, University of California, San Francisco, California, USA.
Graham SimmonsDepartment of Laboratory Medicine, University of California, San Francisco, California, USA.
Mars StoneDepartment of Laboratory Medicine, University of California, San Francisco, California, USA.
Philip L FelgnerDepartment of Physiology and Biophysics, Vaccine Research and Development Laboratory, University of California, Irvine, California, USA.
Rafael R de AssisDepartment of Physiology and Biophysics, Vaccine Research and Development Laboratory, University of California, Irvine, California, USA.
Saahir KhanDivision of Infectious Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Cheng-Ting TsaiEnable Biosciences Inc., South San Francisco, California, USA.
Peter V RobinsonEnable Biosciences Inc., South San Francisco, California, USA.
David SeftelEnable Biosciences Inc., South San Francisco, California, USA.
Johannes IrschCerus Corporation, Concord, California, USA.
Anil BagriCerus Corporation, Concord, California, USA.
Andreas S BuserDepartment of Clinical Research, University Hospital Basel, Basel, Switzerland.ORCID 0000-0002-7942-6746
Laurence CorashCerus Corporation, Concord, California, USA.ORCID 0000-0002-8615-9869
University Hospital of Basel · CHSwiss Red Cross · CHCerus (United States) · USEnable Biosciences (United States) · USUniversity of California, San Francisco · USUniversity of Basel · CHUniversity of California, Irvine · USUniversity Hospital of Geneva · CHUniversity of Geneva · CHUniversity of Southern California · US

Funding

Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
NCATS NIH HHS KL2 TR001416
6 · The paper itself

Abstract

backgroundEfficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics. STUDY DESIGN AND

methodsIn a single-center hypothesis-generating prospective case-control study with 1:2 matched dCCP recipients to controls according to disease severity at day 1, hospitalized adults with COVID-19 pneumonia received 2 × 200 ml pathogen-reduced treated dCCP from 2 different donors. We evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 convalescent plasma donors and recipients using multiple antibody assays including a Coronavirus antigen microarray (COVAM), and binding and neutralizing antibody assays. Outcomes were dCCP characteristics, antibody responses, 28-day mortality, and dCCP -related adverse events in recipients.

resultsEleven of 13 dCCPs (85%) contained neutralizing antibodies (nAb). PRT did not affect dCCP antibody activity. Fifteen CCP recipients and 30 controls (median age 64 and 65 years, respectively) were enrolled. dCCP recipients received 2 dCCPs from 2 different donors after a median of one hospital day and 11 days after symptom onset. One dCCP recipient (6.7%) and 6 controls (20%) died (p = 0.233). We observed no dCCP-related adverse events. Transfusion of unselected dCCP led to heterogeneous SARS CoV-2 antibody responses. COVAM clustered dCCPs in 4 distinct groups and showed endogenous immune responses to SARS-CoV-2 antigens over 14-21 days post dCCP in all except 4 immunosuppressed recipients. DISCUSSION: PRT did not impact dCCP anti-virus neutralizing activity. Transfusion of unselected dCCP did not impact survival and had no adverse effects. Variable dCCP antibodies and post-transfusion antibody responses indicate the need for controlled trials using well-characterized dCCP with informative assays.

Indexed as

COVID-19SARS-CoV-2AgedAntibodies, NeutralizingAntibodies, ViralCase-Control StudiesCOVID-19 SerotherapyHumansImmunization, PassiveMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 convalescent plasmaneutralizing antibodiespathogen-reduction treatmentSARS-CoV2

Identifiers

PMID36054476
PMCPMC9538076
OpenAlexW4292501494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.